Skip to main content

Table 2 Description of the cohort

From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

  Total (n = 84)
No. (%)
Age, years (mean ± SD) (min–max) 49.8 ± 18.70 (18–94)
Age > 65 years old 19 (22.9)
Gender (male) 34 (40.46)
Type of disease
 Myopathy 27 (40.5)
 Neuropathy 23 (27.4)
 Myasthenia 34 (40.5)
Origin of the disease
 Acquired 44 (53.0)
 Genetic 39 (47.0)
Severity of neuromuscular diseaseƗ
 Low 30 (36.6)
 Moderate 36 (43.9)
 High 16 (19.5)
Mobility
 Walk 58 (70.7)
 Walk with help 12 (14.6)
 Wheelchair 12 (14.6)
Comorbidities
 Heart failure 16 (20.3)
 Respiratory failure 28 (35.9)
 Hypertension 11 (13.1)
 Diabetes 10 (11.9)
 Obesity 8 (9.5)
Medication
 Corticosteroids 14 (16.7)
 Other immunosuppressants 17 (20.2)
Diagnosis of COVID-19
 PCR 24 (28.6)
 Thoracic CT-Scan 4 (4.8)
 PCR + Thoracic CT-Scan 20 (23.8)
 Neither § 36 (42.8)
Effect of COVID-19
 Without 48 (57.8)
 Aggravating factor 26 (31.3)
 Death 9 (10.8)
Severity of COVID-19
 Low 48 (57.8)
 Moderate 23 (27.7)
 High 12 (14.5)
Medical care
 Medical unit 23 (27.7)
 Intensive care unit 12 (14.5)
 Home care 48 (57.8)
  1. n number of cases, No. (%) number of cases (% of cases)
  2. ƗAccording to the physician
  3. Prior to COVID-19
  4. §Patients presenting clinical signs highly suggestive of COVID-19 (cough, fever, anosmia, hyposmia, skin signs, myalgia, headache, diarrhea, breathlessness, chest tightness)